NCT00938574

Study With Atu027 in Patients With Advanced Solid Cancer

A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Silence Therapeutics GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as therapy in subjects with advanced solid cancer.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	Atu027

Timeline

• Start date: 2009-06-01
• Primary completion: 2012-07-01
• Completion: 2012-09-01
• First posted: 2009-07-14
• Last updated: 2013-04-09

Locations

1 site across 1 country: Germany